15.482 Healthcare Finance Spring 2017

Andrew W. Lo. Min

Unit 9, Part 1: Risk and Return in the Biopharma Industry

Unit Outline


- Risk and Return in the Biopharma Industries, 1930-2015
- Estimating Clinical Success Rates
- Predicting Phase Transitions and Approvals
- Patient-Centered Clinical Trials


Financial Risk and Return in the Biotech and **Pharmaceutical Industries** from 1930 to 2015


Richard T. Thakor, Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, and Andrew W. Lo (2017)


Stock Market Data on All Biopharma Firms

- January 1930 to December 2015
- All publicly traded biotech and pharma companies (current and defunct): 965 firms after filtering
- Classification into industry using NAICS or GICS
- Neither is perfect; both rarely change over time
- We propose more refined classification: pharma,
 specialty pharma, early biotech, late biotech, other









- 1. Number of Employees
- 2. Intangible Assets
- 3. Revenues
- 4. Research and Development Expenses
- 5. Stock Returns
- 6. Standard deviation of returns
- 7. Value of Total Assets
- 8. Cash Holdings
- 9. Amount of Debt
- 10. Amount of Dividends Paid
- 11. Earnings Before Interest and Taxes (EBIT)


- 12. Property, Plant, and Equipment (PPE)
- 13. Sales
- 14. Months since Initial Public Offering (IPO)
- 15. Number of Products in Pipeline
- 16. Number of Products on Market
- 17. Number of Patents
- 18. Whether Company has Marketing Expenses
- 19. Whether Company has FDA Approvals
- 20. Whether Company has Manufacturing
- 21. Type of Product (Drug, Device, Diagnostic, Other)

- Seed companies for Pharma:
 - Johnson & Johnson, Pfizer Inc., Genentech Inc., Merck and Co., Pfizer Inc., Amgen Inc., and Wyeth.
- Seed companies for Specialty Pharma:
 - Forest Laboratories, Valeant Pharmaceuticals, Gilead Sciences Inc., Jazz Pharmaceuticals PLC, Pacira Pharmaceuticals Inc., Salix Pharmaceuticals LTD, and Shire PLC


- Seed companies for Early Biotech:
 - Accentia Biopharmaceuticals, Conatus Pharmaceuticals Inc.,
 Diacrin Inc., Kindred Biosciences Inc., Opexa Therapeutics
 Inc., Sarepta Therapeutics Inc., Sophiris Bio Inc., and Sorrento
 Thereapeutics Inc.
- Seed companies for Late Biotech:
 - Cor Therapeutics Inc., Dendreon Corp., Discovery
 Laboratories Inc., and Human Genome Sciences Inc.

Other:


 Diagnostics-related companies (e.g., imaging), diagnostics toolkits, assays, etc., devices companies that do a significant portion of business in laboratory equipment design, medical instruments, and manufacturing




Panel A: Continuous Sample from 1930-2015, excluding Biotech




Panel B: Sample from 1930-1980 and 1980-2015, including Biotech




- Results depend on how these 11 companies are classified:
 - Amgen, Gilead, Robins (A.H.), Searle (G.D.), Sepracor, Dura,
 PDL, Taro, Valeant, Syntex, and Mylan




Annual Returns of Biopharma






Profitability




Panel B: Biotech Profitability S 0 Profitability/Total Assets 5 -2 -1.5 -1 -.5 1985 1995 2000 Data Year - Fiscal 2005 2010 2015 1980 1990 5th Percentile 25th Percentile Median 75th Percentile 95th Percentile ---- Mean

CAPM Betas




© 2017 by Andrew W. Lo **All Rights Reserved**

Biopharma Volatility



Biopharma Variance Decomposition



Panel B: Biotech Variance Decomposition 4 3 Variance .2 1980 1985 1990 1995 2000 2005 2010 2015 Systematic Risk Idiosyncratic Risk

Biopharma Performance

	Annualized Mean Returns				Annualized Volatilities				Sharpe Ratios			
Time Period	Market	Tech	Pharma	Biotech	Market	Tech	Pharma	Biotech	Market	Tech	Pharma	Biotech
1930-1934	-10%	-5%	2%	848	0.33	0.37	0.34	=	-0.05	0.06	0.23	: <u>-</u>
1935-1939	10%	11%	15%	:=:	0.21	0.18	0.14	2	0.51	0.56	0.86	2
1940-1944	9%	9%	2%	(5)	0.12	0.11	0.12	ā	0.58	0.61	0.17	5
1945-1949	11%	14%	17%	-	0.13	0.14	0.15	7	0.71	0.84	0.88	5
1950-1954	22%	23%	17%	(-)	0.09	0.11	0.12		1.70	1.44	0.89	Ħ
1955-1959	15%	30%	26%		0.11	0.15	0.15	*	1.10	1.53	1.43	*
1960-1964	10%	10%	11%	(4)	0.10	0.17	0.14	4	0.61	0.43	0.52	=
1965-1969	6%	23%	12%		0.09	0.16	0.11	ఆ	0.18	1.03	0.53	2
1970-1974	-4%	-9%	4%	-	0.15	0.22	0.18	-	-0.48	-0.66	0.03	•
1975-1979	18%	14%	6%		0.11	0.16	0.14	7	0.73	0.45	0.04	
1980-1984	14%	16%	13%	-6%	0.14	0.20	0.15	0.30	0.26	0.33	0.17	-0.28
1985-1989	18%	4%	28%	1%	0.16	0.21	0.21	0.26	0.69	0.00	1.01	-0.03
1990-1994	9%	15%	10%	-4%	0.11	0.18	0.17	0.24	0.36	0.62	0.34	-0.06
1995-1999	27%	46%	34%	16%	0.15	0.26	0.21	0.21	1.39	1.40	1.48	0.48
2000-2004	-1%	-16%	0%	-10%	0.20	0.40	0.23	0.41	-0.15	-0.31	-0.08	0.04
2005-2009	2%	3%	4%	-14%	0.24	0.25	0.18	0.28	0.02	0.11	0.12	-0.46
2010-2015	11%	13%	19%	17%	0.16	0.18	0.16	0.31	0.87	0.82	1.44	0.68
1980-2015	11%	10%	15%	0%	0.17	0.25	0.19	0.29	0.47	0.35	0.66	0.06
1930-1979	8%	11%	11%	12.	0.17	0.19	0.17	1	0.36	0.48	0.47	12
1930-2015	9%	11%	13%		0.17	0.22	0.18	-	0.40	0.42	0.53	

Biopharma Performance

Time Period	Pharma		Biotech	Tech		
1930-1934	0.104		A.	Vi.	0.067	
1935-1939	0.091	*			0.032	
1940-1944	-0.023				0.028	
1945-1949	0.069	*			0.043	
1950-1954	-0.034				0.046	
1955-1959	0.086	**			0.134	***
1960-1964	0.013				-0.017	
1965-1969	0.060	*			0.158	***
1970-1974	0.105	***			-0.020	
1975-1979	-0.109	***			-0.045	
1980-1984	-0.004		-0.153		0.013	
1985-1989	0.065	*	-0.144	**	-0.134	***
1990-1994	0.013		-0.101		0.055	
1995-1999	0.052		-0.068		0.074	
2000-2004	0.015		-0.021		-0.081	
2005-2009	0.017		-0.139	**	0.017	
2010-2015	0.091	**	0.046		0.008	
1980-2015	0.051	*c*c	-0.084	**	-0.010	
1930-1979	0.039	**			0.036	**
1930-2015	0.044	***			0.018	